Previous 10 | Next 10 |
home / stock / lobe:cc / lobe:cc news
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced...
Vancouver, British Columbia--(Newsfile Corp. - July 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced i...
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 st...
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and me...
IIROC Trade Resumption - LOBE Canada NewsWire VANCOUVER, BC , June 9, 2022 /CNW/ - Trading resumes in: Company: Lobe Sciences Ltd. CSE Symbol: LOBE All Issues: Yes Resumption (ET): 9:30 AM 06/10/22 IIROC can make a decision to impose a...
Toronto, Ontario--(Newsfile Corp. - Le 9 juin/June 2022) - Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares. As a result, the o...
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022. The ...
IIROC Trading Halt - LOBE Canada NewsWire VANCOUVER, BC , June 9, 2022 /CNW/ - The following issues have been halted by IIROC: Company: Lobe Sciences Ltd. CSE Symbol: LOBE All Issues: Yes Reason: Pending Clarification of News H...
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") announces that its board of directors has authorized the implementation of a consolidation (the " Consolidation ") of the Company's common shares (the " Sh...
News, Short Squeeze, Breakout and More Instantly...
Company Exploring Alternative Value Creation Opportunities Convertible note for $500,000.00 USD, Short-term Debt Reduced and Balance Sheet Strengthened to Prepare the Company for Long Term Funding Strategy Annual General Meeting Set for 22 July 2024 Lobe Sciences Ltd. (O...
Accomplished Investor and Serial Entrepreneur Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Wesley Ramjeet has agreed to join its Board of Di...
Providing a Proven Track Record of Driving Growth and Innovation Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. ha...